A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity
- PMID: 19086961
- DOI: 10.1111/j.1572-0241.2008.01743.x
A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity
Erratum in
- Am J Gastroenterol. 2009 Apr;104(4):1072. Biroulet, Laurent P [corrected to Peyrin-Biroulet, Laurent]
Retraction in
-
Retraction: A 6-thioguanine nucleotide threshold level of 400 pmol/8x10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.Am J Gastroenterol. 2009 Mar;104(3):801. doi: 10.1038/ajg.2009.101. Am J Gastroenterol. 2009. PMID: 19262535 No abstract available.
Abstract
Background and aims: A therapeutic level of 6-thioguanine nucleotides (6-TGN) has been reported in inflammatory bowel disease (IBD) patients under azathioprine (AZA). We investigated the threshold value of 6-TGN that may be predictive of AZA refractoriness and its impact on safety profile.
Methods: Patients with normal thiopurine methyltransferase (TPMT) activity (7.5-14 U/mL erythrocytes), suffering from steroid-dependent or active IBD despite AZA use for at least 6 months, were prospectively included. Clinical efficacy, adverse events, and thiopurine metabolite levels were recorded at baseline, 1 month after each dose escalation, and thereafter every 3 months.
Results: Fifty-five patients were included (43 with Crohn's disease, 12 with ulcerative colitis). After a mean follow-up of 12 months, 31 patients (56.3%) did not reach clinical remission despite a gradual increase in AZA dose and 6-TGN level of >400 pmol/8 x 10(8) erythrocytes, and were considered refractory to AZA (sensitivity 45%, specificity 100%). Adverse events occurred more frequently in these patients than in responders (42%vs 25%, respectively, P= 0.02). Among 55 patients, 15 cases of myelotoxicity associated with elevated levels of total methylated metabolites (14,500 pmol/8 x 10(8) erythrocytes vs 5,230 pmol/8 x 10(8) erythrocytes in patients without myelotoxicity, P= 0.03) were observed. Patients with total methylated metabolites of >11,100 pmol/8 x 10(8) erythrocytes had an increased risk of developing myelotoxicity (odds ratio [OR] 11.0, 95% confidence interval [CI] 1.1-250, P= 0.05).
Conclusion: A 6-TGN level of >400 pmol/8 x 10(8) erythrocytes in IBD patients with normal TPMT activity and steroid-dependent or active disease despite an optimal AZA regimen may predict refractoriness to this drug. Furthermore, high levels of methylated derivatives are associated with an increased risk of myelotoxicity.
Comment in
-
Comment on a retraction.Am J Gastroenterol. 2009 May;104(5):1334. doi: 10.1038/ajg.2009.198. Epub 2009 Apr 14. Am J Gastroenterol. 2009. PMID: 19367265 No abstract available.
Similar articles
-
Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.Dig Liver Dis. 2008 Jun;40(6):425-32. doi: 10.1016/j.dld.2008.01.003. Epub 2008 Mar 4. Dig Liver Dis. 2008. PMID: 18304898 Clinical Trial.
-
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.Ther Drug Monit. 2007 Feb;29(1):1-5. doi: 10.1097/FTD.0b013e3180312b9a. Ther Drug Monit. 2007. PMID: 17304143 Clinical Trial.
-
Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.Scand J Gastroenterol. 2004 Nov;39(11):1105-12. doi: 10.1080/00365520410007980. Scand J Gastroenterol. 2004. PMID: 15545169
-
Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.J Gastroenterol Hepatol. 2005 Aug;20(8):1149-57. doi: 10.1111/j.1440-1746.2005.03832.x. J Gastroenterol Hepatol. 2005. PMID: 16048561 Review.
-
Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.Aliment Pharmacol Ther. 2012 Jan;35(1):15-36. doi: 10.1111/j.1365-2036.2011.04905.x. Epub 2011 Nov 2. Aliment Pharmacol Ther. 2012. PMID: 22050052 Review.
Cited by
-
6-Mercaptopurine transport in human lymphocytes: correlation with drug-induced cytotoxicity.J Dig Dis. 2012 Feb;13(2):82-93. doi: 10.1111/j.1751-2980.2011.00556.x. J Dig Dis. 2012. PMID: 22257476 Free PMC article.
-
New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer via small molecule potentiators.Medchemcomm. 2019 Mar 18;10(5):717-725. doi: 10.1039/c9md00010k. eCollection 2019 May 1. Medchemcomm. 2019. PMID: 31191862 Free PMC article.
-
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.Medchemcomm. 2018 Dec 20;10(1):169-179. doi: 10.1039/c8md00463c. eCollection 2019 Jan 1. Medchemcomm. 2018. PMID: 30774864 Free PMC article.
-
Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.World J Gastroenterol. 2014 Mar 28;20(12):3327-34. doi: 10.3748/wjg.v20.i12.3327. World J Gastroenterol. 2014. PMID: 24696613 Free PMC article.
-
The Role of Laboratory Tests in Crohn's Disease.Clin Med Insights Gastroenterol. 2016 Aug 18;9:51-62. doi: 10.4137/CGast.S38203. eCollection 2016. Clin Med Insights Gastroenterol. 2016. PMID: 27656094 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous